After the obtaining of Marketing Authorisation by EMA in the early days of June, Bluebird Bio annouces a price for Zynteglo, its gene therapy for the treatment of transfusion-dependent β-thalassemia in patients without donors for hematopoietic stem cell transplantation, of €1.575 millions; payers only pay if Zynteglo works, with a €315.000 advance payment and 5 annual instalments. According to the company, ability to avoid transfusions and to improve patient’s quality of life justifies the price